Cargando…

Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study

OBJECTIVE: Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarendran, Balachandran, O'Reilly, Michael W., Subramanian, Anuradhaa, Šumilo, Dana, Toulis, Konstantinos, Gokhale, Krishna M., Wijeratne, Chandrika N., Coomarasamy, Arri, Tahrani, Abd A., Azoulay, Laurent, Arlt, Wiebke, Nirantharakumar, Krishnarajah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669537/
https://www.ncbi.nlm.nih.gov/pubmed/34649997
http://dx.doi.org/10.2337/dc21-0437
_version_ 1784614799509815296
author Kumarendran, Balachandran
O'Reilly, Michael W.
Subramanian, Anuradhaa
Šumilo, Dana
Toulis, Konstantinos
Gokhale, Krishna M.
Wijeratne, Chandrika N.
Coomarasamy, Arri
Tahrani, Abd A.
Azoulay, Laurent
Arlt, Wiebke
Nirantharakumar, Krishnarajah
author_facet Kumarendran, Balachandran
O'Reilly, Michael W.
Subramanian, Anuradhaa
Šumilo, Dana
Toulis, Konstantinos
Gokhale, Krishna M.
Wijeratne, Chandrika N.
Coomarasamy, Arri
Tahrani, Abd A.
Azoulay, Laurent
Arlt, Wiebke
Nirantharakumar, Krishnarajah
author_sort Kumarendran, Balachandran
collection PubMed
description OBJECTIVE: Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS. RESEARCH DESIGN AND METHODS: Using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices), we carried out a retrospective population-based cohort study to determine dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up). Cox models were used to estimate the unadjusted and adjusted hazard ratio, and conditional logistic regression was used to obtain adjusted odds ratios (aORs). RESULTS: The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78–1.97, P < 0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a reduced dysglycemia risk (aOR 0.72, 95% CI 0.59–0.87). CONCLUSIONS: In this study, limited by its retrospective nature and the use of routinely collected electronic general practice record data, which does not allow for exclusion of the impact of prescription-by-indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia across all BMI subgroups. Future prospective studies should be considered for further understanding of these observations and potential causality.
format Online
Article
Text
id pubmed-8669537
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-86695372021-12-28 Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study Kumarendran, Balachandran O'Reilly, Michael W. Subramanian, Anuradhaa Šumilo, Dana Toulis, Konstantinos Gokhale, Krishna M. Wijeratne, Chandrika N. Coomarasamy, Arri Tahrani, Abd A. Azoulay, Laurent Arlt, Wiebke Nirantharakumar, Krishnarajah Diabetes Care Cardiovascular and Metabolic Risk OBJECTIVE: Irregular menstrual cycles are associated with increased cardiovascular mortality. Polycystic ovary syndrome (PCOS) is characterized by androgen excess and irregular menses; androgens are drivers of increased metabolic risk in women with PCOS. Combined oral contraceptive pills (COCPs) are used in PCOS both for cycle regulation and to reduce the biologically active androgen fraction. We examined COCP use and risk of dysglycemia (prediabetes and type 2 diabetes) in women with PCOS. RESEARCH DESIGN AND METHODS: Using a large U.K. primary care database (The Health Improvement Network [THIN]; 3.7 million patients from 787 practices), we carried out a retrospective population-based cohort study to determine dysglycemia risk (64,051 women with PCOS and 123,545 matched control subjects), as well as a nested pharmacoepidemiological case-control study to investigate COCP use in relation to dysglycemia risk (2,407 women with PCOS with [case subjects] and without [control subjects] a diagnosis of dysglycemia during follow-up). Cox models were used to estimate the unadjusted and adjusted hazard ratio, and conditional logistic regression was used to obtain adjusted odds ratios (aORs). RESULTS: The adjusted hazard ratio for dysglycemia in women with PCOS was 1.87 (95% CI 1.78–1.97, P < 0.001; adjustment for age, social deprivation, BMI, ethnicity, and smoking), with increased rates of dysglycemia in all BMI subgroups. Women with PCOS and COCP use had a reduced dysglycemia risk (aOR 0.72, 95% CI 0.59–0.87). CONCLUSIONS: In this study, limited by its retrospective nature and the use of routinely collected electronic general practice record data, which does not allow for exclusion of the impact of prescription-by-indication bias, women with PCOS exposed to COCPs had a reduced risk of dysglycemia across all BMI subgroups. Future prospective studies should be considered for further understanding of these observations and potential causality. American Diabetes Association 2021-12 2021-10-15 /pmc/articles/PMC8669537/ /pubmed/34649997 http://dx.doi.org/10.2337/dc21-0437 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.
spellingShingle Cardiovascular and Metabolic Risk
Kumarendran, Balachandran
O'Reilly, Michael W.
Subramanian, Anuradhaa
Šumilo, Dana
Toulis, Konstantinos
Gokhale, Krishna M.
Wijeratne, Chandrika N.
Coomarasamy, Arri
Tahrani, Abd A.
Azoulay, Laurent
Arlt, Wiebke
Nirantharakumar, Krishnarajah
Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title_full Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title_fullStr Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title_full_unstemmed Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title_short Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study
title_sort polycystic ovary syndrome, combined oral contraceptives, and the risk of dysglycemia: a population-based cohort study with a nested pharmacoepidemiological case-control study
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669537/
https://www.ncbi.nlm.nih.gov/pubmed/34649997
http://dx.doi.org/10.2337/dc21-0437
work_keys_str_mv AT kumarendranbalachandran polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT oreillymichaelw polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT subramaniananuradhaa polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT sumilodana polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT touliskonstantinos polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT gokhalekrishnam polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT wijeratnechandrikan polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT coomarasamyarri polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT tahraniabda polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT azoulaylaurent polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT arltwiebke polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy
AT nirantharakumarkrishnarajah polycysticovarysyndromecombinedoralcontraceptivesandtheriskofdysglycemiaapopulationbasedcohortstudywithanestedpharmacoepidemiologicalcasecontrolstudy